RT Journal
A1 Dodwell E, Snyder B, Wright J
T1 OFf-label use of bone morphogenetic proteins in pediatric spinal arthrodesis
JF JAMA
JO JAMA
YR 2012
FD October 10
VO 308
IS 14
SP 1429
OP 1432
DO 10.1001/jama.2012.12929
UL http://dx.doi.org/10.1001/jama.2012.12929
AB 
Bone morphogenetic proteins (BMPs) are approved for limited use in adults when healing may be suboptimal.2- 3 In addition to concerns about possible carcinogenesis, complications include wound dehiscence, spinal stenosis, and respiratory complications.4 The US Food and Drug Administration has not approved the use of BMPs in children.